Carr M, May F E, Lennard T W, Westley B R
Department of Pathology, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
Br J Cancer. 1995 Dec;72(6):1427-34. doi: 10.1038/bjc.1995.525.
Competitive polymerase chain reaction assays have been developed for the quantitation of oestrogen receptor mRNA and two oestrogen-regulated mRNAs (progesterone receptor and pNR-2/pS2) in breast cancer cells. These assays are more sensitive than traditional hybridisation techniques, do not require the use of radioisotopes, measure absolute amounts of messenger RNAs and can be used to measure the expression of mRNAs in small numbers of tumour cells obtained by fine-needle aspiration (FNA). These assays should prove useful for predicting the hormone responsiveness of breast cancer from tumour cells obtained by FNA at diagnosis and could be particularly useful in the management of elderly/frail patients who receive primary tamoxifen, or in other patients for whom tumour tissue for standard biochemical measurements is not available.
已经开发出竞争性聚合酶链反应分析法,用于定量乳腺癌细胞中雌激素受体mRNA以及两种雌激素调节的mRNA(孕激素受体和pNR-2/pS2)。这些分析法比传统杂交技术更灵敏,无需使用放射性同位素,可测量信使RNA的绝对量,并且可用于测量通过细针穿刺(FNA)获得的少量肿瘤细胞中mRNA的表达。这些分析法对于从诊断时通过FNA获得的肿瘤细胞预测乳腺癌的激素反应性应是有用的,并且在接受原发性他莫昔芬治疗的老年/体弱患者或无法获得用于标准生化测量的肿瘤组织的其他患者的管理中可能特别有用。